The 22G Franseen Needle Combined With Different Aspiration Techniques for Endoscopic Ultrasound-guided Fine-needle Biopsy

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorChanghai Hospital

About this trial

The goal of this clinical study is to compare the tissue adequacy, cellularity, blood contamination, accuracy, sensitivity, specificity of the 22G Franseen needle combined with three different suction techniques (dry-suction, wet-suction, and slow-pull) in Endoscopic ultrasound-guided fine-needle biopsy for solid pancreatic lesions.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

contraindications to endoscopy, such as severe cardiovascular and cerebrovascular diseases;

bleeding coagulation dysfunction (prothrombin international normalized ratio ≥1.5, platelet count ≤ 50 000) or use of antiplatelet drugs;

confirmed pregnancy or possible pregnancy;

pathological diagnosis has been obtained by other methods;

Trial design

Design model

Crossover

Treatments tested in this trial

  • ABC

    Procedure/Surgery

    Suction sampling should be conducted in the sequence of dry-suction, slow-pull and wet-suction.

  • ACB

    Procedure/Surgery

    Suction sampling should be conducted in the sequence of dry-suction, wet-suction and slow-pull.

  • BAC

    Procedure/Surgery

    Suction sampling should be conducted in the sequence of slow-pull, dry-suction and wet-suction.

  • BCA

    Procedure/Surgery

    Suction sampling should be conducted in the sequence of slow-pull, wet-suction and dry-suction.

  • CAB

    Procedure/Surgery

    Suction sampling should be conducted in the sequence of wet-suction, dry-suction and slow-pull.

  • CBA

    Procedure/Surgery

    Suction sampling should be conducted in the sequence of wet-suction, slow-pull and dry-suction.

Treatment groups

270 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Group A: ABC groupExperimental treatment 1 intervention
Group B: ACB groupExperimental treatment 1 intervention
Group C: BAC groupExperimental treatment 1 intervention
Group D: BCA groupExperimental treatment 1 intervention
Group E: CAB groupExperimental treatment 1 intervention
Group F: CBA groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Tissue adequacy

Grade A, existing core tissue (defined as structurally intact tissue with a long axis length of at least 550 μm) that clearly characterizes the lesion and is sufficient for diagnosis; Grade B, the presence of core fragments that do not meet the histological criteria for structural integrity, but can still be diagnosed based on cell morphology; Grade C, no diseased tissue is found and no diagnosis can be made based on the sample.

Time frame
2 months

Secondary outcomes

1

Cellularity

Grade A: Satisfactory, with more than 4 clusters, each containing at least 10 cells for cytological analysis; Grade B: Adequate, with 2-4 clusters, each containing at least 10 cells for cytological analysis; Grade C: Insufficient, with\<2 clusters suitable for cytological analysis or non-representative samples, or\<50 cells with clear nuclear structures.

Time frame
2 months
2

Blood contamination

The histological blood contamination score is assessed by grading the percentage of red blood cells in the entire 40x magnified field of view. Grade A: Red blood cells are present in\<25%of the slides; Grade B: Red blood cells occupy 25%-50%of the slide; Grade C: Red blood cells are present in\>50%of the slides; Grade D: No tissue.

Time frame
2 months
3

Diagnostic accuracy

Diagnostic accuracy was calculated as the proportion of true positive and true negative in all evaluated cases.

Time frame
6 months
4

Diagnostic sensitivity

Diagnostic sensitivity was calculated as the proportion of true positives in patient cases.

Time frame
6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: